Bracco forms unit to develop therapeutic radiopharmaceuticals

AuntMinnie.com staff writers
Mar 1, 2022
2020 10 16 23 20 7849 Bracco2 Rsna 2018 400

Bracco Imaging has launched a new subsidiary called Blue Earth Therapeutics to advance the development of radiopharmaceutical technology.

Initially, Blue Earth Therapeutics is building a portfolio of precision-targeted radiopharmaceuticals focused on prostate cancer. In the future, it will expand to additional diseases in oncology.

Also, the subsidiary has exclusive rights to therapeutic applications of radiohybrid prostate-specific membrane antigen radiopharmaceutical technology. David Gauden, PhD, is CEO of Blue Earth Therapeutics.

Latest in Molecular Imaging
There are several conceivable advantages of F-18 FDG PET/CT over conventional imaging. Image A and B showing an example of the distinctive capability of the F-18 FDG PET/CT. A shows a fusion image of F-18 FDG PET/CT and low-dose CT and B an high resolution chest CT of a patient with an Aspergillus infection. The suspected aspergilloma is concealed on the high resolution CT due to the lung fluids and consolidation. Image C and D (fusion image of F-18 FDG PET/CT and low-dose CT and low-dose CT only, respectively) are examples of the ability to image inflammation while no concurrent abnormalities are visualized, in this case prostatitis (red arrows). Image E, a maximized intensity projection of F-18 FDG PET, shows a patient with lung infections and multiple muscle abscesses after MRSA sepsis. This is an illustrative example of a relevant dissemination investigation. Image and caption available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Annals of Intensive Care.
PET/CT reveals new infections in ICU patients
February 21, 2025
New! Imaging Life Issue 20 now available
Sponsored
New! Imaging Life Issue 20 now available
January 1, 2025
Ga-68 FZ-NR-1 PET/CT images and F-18 FDG PET/CT and PET/MRI images in representative nectin-4-positive TNBC patients. (A) PET/CT images and nectin-4 immunohistochemistry (IHC) staining of patient 1. Maximum-intensity projection (MIP) images and axial and coronal PET/CT images of Ga-68 FZ-NR-1 and F-18 FDG both showed high uptake in lung metastases (arrow). (B) PET/CT images and nectin-4 IHC staining of patient 2. MIP images and axial and coronal PET/CT images of Ga-68 FZ-NR-1 showed high uptake in recurrence of right breast cancer after surgery (arrow), and those of F-18 FDG PET/MRI showed high uptake. Image courtesy of the Journal of Nuclear Medicine.
New PET tracer developed for breast cancer
February 14, 2025
Kidneys
Pluvicto safe in patients with impaired kidneys
February 13, 2025
        An unexpected error occurred: Network error: Response not successful: Received status code 500
      
            [
  {
    "message": "Cannot execute GraphQL operations after the server has stopped.",
    "extensions": {
      "code": "INTERNAL_SERVER_ERROR"
    }
  }
]
More in Molecular Imaging
PET/CT reveals new infections in ICU patients
By Will Morton
F-18 FDG-PET/CT is a valuable approach for diagnosing unknown infections in intensive care unit (ICU) patients.
February 21, 2025
There are several conceivable advantages of F-18 FDG PET/CT over conventional imaging. Image A and B showing an example of the distinctive capability of the F-18 FDG PET/CT. A shows a fusion image of F-18 FDG PET/CT and low-dose CT and B an high resolution chest CT of a patient with an Aspergillus infection. The suspected aspergilloma is concealed on the high resolution CT due to the lung fluids and consolidation. Image C and D (fusion image of F-18 FDG PET/CT and low-dose CT and low-dose CT only, respectively) are examples of the ability to image inflammation while no concurrent abnormalities are visualized, in this case prostatitis (red arrows). Image E, a maximized intensity projection of F-18 FDG PET, shows a patient with lung infections and multiple muscle abscesses after MRSA sepsis. This is an illustrative example of a relevant dissemination investigation. Image and caption available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Annals of Intensive Care.
PSMA-PET tracer performs well in clinical trial
By Will Morton
PET/CT imaging with a new gallium-68-based prostate cancer radiotracer shows promise for detecting recurrent metastatic disease.
February 20, 2025
(A) Representative maximum-intensity projection and selected PET/CT images (fused, PET and CT only) of patient with metastatic prostate cancer at 1 hour after injection. (B and C) Low uptake of Ga-68 PSMA-R2 in salivary and submandibular glands is also demonstrated. (D) Images show heterogeneous uptake of Ga-68 PSMA-R2 with varying degrees of intensity in multiple spine bone lesions (vertebral sclerotic lesion with intense PSMA-R2 expression at its periphery indicated with red arrow). HU = Houndsfield unit; SUVbw = body-weight SUV. Images and caption courtesy of the Journal of Nuclear Medicine.
New PET tracer developed for breast cancer
By Will Morton
A new PET radiotracer shows promise for diagnosing triple-negative breast cancer.
February 14, 2025
Ga-68 FZ-NR-1 PET/CT images and F-18 FDG PET/CT and PET/MRI images in representative nectin-4-positive TNBC patients. (A) PET/CT images and nectin-4 immunohistochemistry (IHC) staining of patient 1. Maximum-intensity projection (MIP) images and axial and coronal PET/CT images of Ga-68 FZ-NR-1 and F-18 FDG both showed high uptake in lung metastases (arrow). (B) PET/CT images and nectin-4 IHC staining of patient 2. MIP images and axial and coronal PET/CT images of Ga-68 FZ-NR-1 showed high uptake in recurrence of right breast cancer after surgery (arrow), and those of F-18 FDG PET/MRI showed high uptake. Image courtesy of the Journal of Nuclear Medicine.
Pluvicto safe in patients with impaired kidneys
By Will Morton
Lu-177 prostate-specific membrane antigen-617 (Lu-177 PSMA-617, Pluvicto) may be safely delivered in patients with impaired renal function.
February 13, 2025
Kidneys
Dosimetry key in Lu-177 cancer therapy
By Will Morton
Personalized medicine is rapidly evolving in cancer theranostics, with technology now available that allows clinicians to optimize doses of radiopharmaceuticals on an individual patient level, according to experts.
February 5, 2025
Kesner Zanzonico
PET/CT guides surgery for primary aldosteronism
By Will Morton
PET/CT imaging with gallium-68 pentixafor can effectively guide surgery for patients with primary aldosteronism, a common cause of hypertension.
January 30, 2025
Apa 679bd41fd4afc Thumbnail
New guidance issued on FAP-PET imaging
By Will Morton
Top U.S. and European nuclear medicine organizations have issued joint guidelines on the use of fibroblast activation protein (FAP)-PET imaging in cancer patients.
January 27, 2025
Cancer Target
Is herpes infection protective in early Alzheimer’s disease patients?
By Will Morton
In a recent PET study with “unexpected” results, patients infected with herpes had fewer signs of brain deposits associated with Alzheimer’s disease than uninfected patients.
January 24, 2025
Amyloid
What brain mechanisms drive depression in older adults?
By Will Morton
PET has revealed that mechanisms other than amyloid brain deposits may underlie depressive symptoms in people later in life.
January 23, 2025
Ad
PET/CT can rule out CAV in heart transplant patients
By Will Morton
Cardiac PET/CT scans can effectively rule out moderate to severe cardiac allograft vasculopathy (CAV) in heart transplant patients.
January 17, 2025
Ctca
FAPI-PET shows promise for imaging gastric cancers
By Will Morton
Gallium-68 fibroblast activation protein inhibitor (FAPI) PET/CT is a promising new method for imaging gastric cancer.
January 16, 2025
Fapi Pet Gastric Cancer Thumbnail
PET tracks long-term changes in patients with dementia
By Will Morton
PET imaging can assess brain metabolism changes over time in individuals with prodromal dementia with Lewy bodies (DLB) and probable DLB.
January 13, 2025
Ad
Page 1 of 600
Next Page